MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

25.6 -6.54

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.15

Max

27.39

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

-67M

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-9.8M

-73M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+101.1% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-25

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

196M

1.7B

Ankstesnė atidarymo kaina

32.14

Ankstesnė uždarymo kaina

25.6

Naujienos nuotaikos

By Acuity

50%

50%

173 / 370 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-12 23:54; UTC

Rinkos pokalbiai

CBA Could Underperform Again in 2026 -- Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2026-01-12 23:43; UTC

Rinkos pokalbiai

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026-01-12 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

2026-01-12 21:56; UTC

Rinkos pokalbiai

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

2026-01-12 20:54; UTC

Uždarbis

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

2026-01-12 20:48; UTC

Rinkos pokalbiai

Oil Futures Settle Higher in Choppy Trade -- Market Talk

2026-01-12 20:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

2026-01-12 19:39; UTC

Rinkos pokalbiai

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Gold and Silver Set New Records on Fed Probe -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 19:33; UTC

Rinkos pokalbiai

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

2026-01-12 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

2026-01-12 19:22; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

2026-01-12 18:21; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

2026-01-12 18:20; UTC

Įsigijimai, susijungimai, perėmimai

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

2026-01-12 18:19; UTC

Rinkos pokalbiai

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

2026-01-12 18:16; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Baidu's Outlook Bodes Well For Shares -- Market Talk

2026-01-12 18:01; UTC

Įsigijimai, susijungimai, perėmimai

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

2026-01-12 18:00; UTC

Rinkos pokalbiai

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

101.1% į viršų

12 mėnesių prognozė

Vidutinis 55 USD  101.1%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

173 / 370 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat